Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  Protalix BioTherapeutics Inc.    PLX   US74365A1016

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
02/23/2015 02/24/2015 02/25/2015 02/26/2015 02/27/2015 Date
2(c) 1.96(c) 2(c) 1.97(c) 1.92 Last
318 310 239 229 110 088 109 577 58 084 Volume
+2.04% -2.00% +2.04% -1.50% -2.54% Change
More quotes
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More Ratings
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
PER 2013 -
PER 2014
Capi. / Sales 2013 11,7x
Capi. / Sales 2014 5,16x
Capitalization 185 M
More Financials
Latest news on PROTALIX BIOTHERAPEUTICS I
02/12 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
02/12 Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clin..
02/11 PROTALIX BIOTHERAPEUTICS : Not Just Braces Anymore. Apple Orthodontix Taps Prost..
02/02 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
02/02 Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of..
01/08 PROTALIX BIOTHERAPEUTICS : jumps on positive Fabry disease trial results
01/08 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
01/08 Protalix BioTherapeutics Reports Positive Interim Data From Phase I/II Clinic..
More news
Sector news Biotechnology & Medical Research - NEC
02:46p PHARMACYCLICS : Provides Clinical Update on BTK Inhibitor for Autoimmune Disease..
10:25a ISIS PHARMACEUTICALS : beats Street 4Q forecasts
09:44a ISIS PHARMACEUTICALS : Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx P..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF